Immune Gene Expression Analysis for Breast Cancer Longevity Prediction

The patent segments the prognostic assessment by separating the longevity prediction from traditional factors like age and recurrence status. It divides the gene expression profile into specific immune-related genes (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17) that independently predict longevity, allowing clinicians to assess survival probability without confounding effects from age or recurrence

The patent changes the parameter basis for prediction from demographic and clinical factors (age, recurrence status) to molecular parameters (immune gene expression levels). By measuring the expression levels of specific immune genes and comparing them to reference values, the method provides a novel parameter set that independently predicts longevity, thereby improving both prediction accuracy and reliability

The patent applies local quality by tailoring treatment intensity to individual patients based on their specific immune gene expression profiles. Instead of uniform treatment, each patient receives treatment adapted to their predicted longevity category (above or below reference values), making the treatment quality locally optimized for each patient's prognostic needs

The patent introduces an intermediary prognostic assessment system that mediates between standardized treatment protocols and individual patient needs. The immune gene expression analysis serves as an intermediary tool that translates molecular data into actionable prognostic information, enabling personalized treatment decisions without requiring complex clinical judgment for each case